Summary

Global haemophilia treatment market was valued at USD13906.45 million in 2020 and is forecast to reach USD24205.39 million in 2026 by registering a CAGR of 9.06% during the forecast period. The global haemophilia treatment market is driven by increasing awareness campaigns regarding haemophilia among the population across the globe. Moreover, ongoing attempts in research and development activities for the development of new therapy solutions is positively impacting the growth of the market. Also, surging incidences of bleeding disorders have been observed worldwide, which is further expected to bolster the growth of market over the next few years.
The global haemophilia treatment market is segmented based on type, product, treatment, therapy, company and region. Based on type, the market can be categorized into Haemophilia A, Haemophilia B and Haemophilia C. Generally, the classification depends on the deficiency of coagulation factor present in a patient. Based on that, type A is the most frequent type, and the prevalence rate has been recorded to be four times more than haemophilia type B. In addition to this, majority of existing products are used for treating type A haemophilia, which is contributing to the increasing growth of the segment over the coming years.
Regionally, the market is segregated into North America, Europe, Asia- Pacific, South America and Middle East and Africa. Out of which, North America dominated the global haemophilia treatment market in 2020 owing to increased prevalence of haemophilia A & B in the United States and Canada. Besides this, organic and inorganic strategies of major pharmaceutical companies present in the United States is further contributing to the market growth in the region. Additionally, Asia Pacific region is expected to grow at the fastest rate in the coming years. This high growth can be ascribed to the ease of regulatory policies in Australia and Japan for the approval of drugs for the treatment of haemophilia A. In addition to this, improved funding by public and private players for the improvisation of healthcare facilities in India and China, is further anticipated the drive the market growth in Asia Pacific.
Major players operating in the global haemophilia treatment market include Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, Pfizer, Inc., Takeda Pharmaceutical Company, Sanofi S.A., CSL Behring LLC, BioMarin Pharmaceutical Inc., Octapharma AG, Sangamo Therapeutics Inc., Eagle Pharmaceuticals Inc., Baxter International, Inc., Grifols SA, Biogen Idec, Inc., Alnylam Pharmaceuticals Inc., and others. The companies are adopting new strategies in order to stay competitive in the market. Rising competitiveness is anticipated to drive innovation in the market, therefore helping the industry to solve existing challenges and meet the unmet needs in the market. Besides, these major market players are focusing on new product development, mergers and acquisitions, and business expansion to attain a higher market share.
Years considered for this report:
Historical Years: 2016-2019
Base Year: 2020
Estimated Year: 2021
Forecast Period: 2022–2026
Objective of the Study:
• To analyze the historical growth in the market size of global haemophilia treatment market from 2016 to 2020.
• To estimate and forecast the market size of global haemophilia treatment market from 2021 to 2026 and growth rate until 2026.
• To classify and forecast global haemophilia treatment market based on type, product, treatment, therapy, company and regional distribution.
• To identify dominant region or segment in the global haemophilia treatment market.
• To identify drivers and challenges for global haemophilia treatment market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global haemophilia treatment market.
• To conduct pricing analysis for global haemophilia treatment market.
• To identify and analyze the profile of leading players operating in global haemophilia treatment market.
• To identify key sustainable strategies adopted by market players in global haemophilia treatment market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals/labs and presence of all major players across the globe.
TechSci Research calculated the market size of global haemophilia treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.
Key Target Audience:
• Haemophilia treatment facilities, companies and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to haemophilia treatment
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, global haemophilia treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Global Haemophilia Treatment Market, By Type:
o Haemophilia A
o Haemophilia B
o Haemophilia C
• Global Haemophilia Treatment Market, By Product:
o Recombinant Coagulation Factor Concentrates
o Plasma Derived Coagulation Factor Concentrate
o Desmopressin
o Antifibrinolytics Agents
• Global Haemophilia Treatment Market, By Treatment:
o On-demand
o Prophylaxis
• Global Haemophilia Treatment Market, By End-user:
o Replacement Therapy
o ITI therapy
o Gene Therapy
• Global Haemophilia Treatment Market, By Region:
o North America
 United States
 Canada
 Mexico
o Europe
 Germany
 United Kingdom
 France
 Italy
 Spain
o Asia-Pacific
 India
 China
 Japan
 Australia
 South Korea
o South America
 Brazil
 Argentina
 Colombia
o Middle East & Africa
 Saudi Arabia
 UAE
 South Africa
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global haemophilia treatment market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five)

ページTOPに戻る

Table of Contents

1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on Global Haemophilia Treatment Market
4. Executive Summary
5. Voice of Customer
5.1. Brand Awareness
5.2. Unmet Needs & Challenges
5.3. Factors Influencing Drug Purchase
6. Global Haemophilia Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Haemophilia A, Haemophilia B, Haemophilia C)
6.2.2. By Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents)
6.2.3. By Treatment (On-demand and Prophylaxis)
6.2.4. By Therapy (Replacement Therapy, ITI Therapy and Gene Therapy)
6.2.5. By Company (2020)
6.2.6. By Region
6.3. Product Market Map
7. North America Haemophilia Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Product
7.2.3. By Treatment
7.2.4. By Therapy
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Haemophilia Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Product
7.3.1.2.3. By Treatment
7.3.1.2.4. By Therapy
7.3.2. Canada Haemophilia Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Product
7.3.2.2.3. By Treatment
7.3.2.2.4. By Therapy
7.3.3. Mexico Haemophilia Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Product
7.3.3.2.3. By Treatment
7.3.3.2.4. By Therapy
8. Europe Haemophilia Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Product
8.2.3. By Treatment
8.2.4. By Therapy
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. Germany Haemophilia Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Product
8.3.1.2.3. By Treatment
8.3.1.2.4. By Therapy
8.3.2. United Kingdom Haemophilia Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Product
8.3.2.2.3. By Treatment
8.3.2.2.4. By Therapy
8.3.3. France Haemophilia Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Product
8.3.3.2.3. By Treatment
8.3.3.2.4. By Therapy
8.3.4. Italy Haemophilia Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Product
8.3.4.2.3. By Treatment
8.3.4.2.4. By Therapy
8.3.5. Spain Haemophilia Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Product
8.3.5.2.3. By Treatment
8.3.5.2.4. By Therapy
9. Asia-Pacific Haemophilia Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Product
9.2.3. By Treatment
9.2.4. By Therapy
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. India Haemophilia Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Product
9.3.1.2.3. By Treatment
9.3.1.2.4. By Therapy
9.3.2. China Haemophilia Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Product
9.3.2.2.3. By Treatment
9.3.2.2.4. By Therapy
9.3.3. Japan Haemophilia Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Product
9.3.3.2.3. By Treatment
9.3.3.2.4. By Therapy
9.3.4. Australia Haemophilia Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By Product
9.3.4.2.3. By Treatment
9.3.4.2.4. By Therapy
9.3.5. South Korea Haemophilia Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Type
9.3.5.2.2. By Product
9.3.5.2.3. By Treatment
9.3.5.2.4. By Therapy
10. South America Haemophilia Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Product
10.2.3. By Treatment
10.2.4. By Therapy
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Haemophilia Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Product
10.3.1.2.3. By Treatment
10.3.1.2.4. By Therapy
10.3.2. Argentina Haemophilia Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Product
10.3.2.2.3. By Treatment
10.3.2.2.4. By Therapy
10.3.3. Colombia Haemophilia Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Product
10.3.3.2.3. By Treatment
10.3.3.2.4. By Therapy
11. Middle East and Africa Haemophilia Treatment Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type
11.2.2. By Product
11.2.3. By Treatment
11.2.4. By Therapy
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. Saudi Arabia Haemophilia Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Product
11.3.1.2.3. By Treatment
11.3.1.2.4. By Therapy
11.3.2. UAE Haemophilia Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Product
11.3.2.2.3. By Treatment
11.3.2.2.4. By Therapy
11.3.3. South Africa Haemophilia Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Product
11.3.3.2.3. By Treatment
11.3.3.2.4. By Therapy
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Novo Nordisk A/S
14.2. F. Hoffmann-La Roche AG
14.3. Bayer AG
14.4. Pfizer, Inc.
14.5. Takeda Pharmaceutical Company
14.6. Sanofi S.A.
14.7. CSL Behring LLC
14.8. BioMarin Pharmaceutical Inc.
14.9. Octapharma AG
14.10. Sangamo Therapeutics Inc.
14.11. Eagle Pharmaceuticals Inc.
14.12. Baxter International, Inc.
14.13. Grifols SA
14.14. Biogen Idec, Inc.
14.15. Alnylam Pharmaceuticals Inc.
15. Strategic Recommendations
16. About Us & Disclaimer